DEBRICALM
4A SANTE
Identification
- Active ingredient (INN)
- TRIMEBUTINE MALEATE
- Internal code
- 10 F 095
- Country of Origin
- Algeria
- Pharmaceutical form
- Suppository
- Prescription List
- Regulated (List II)
- Packaging
- b/10
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
This medicine is indicated in adults for the symptomatic treatment of pain associated with functional disorders of the digestive tract.
Associated Conditions
This medicinal product contains lactose.
Patients with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases) should not take this medicine.
This medicinal product contains less than 1 mmol (23 mg) sodium per tablet, i.e. essentially "sodium-free".
Mechanism of Action
Pharmacotherapeutic group
Musculotropic antispasmodic.
- ATC code: A03AA05. (A: digestive apparatus and metabolism) Trimebutin effects are exercised in the digestive tract on the intestinal motor.
Trimebutin has enkephalinergic agonist properties.
It stimulates the intestinal motor by triggering phase III waves propagated by the migrating motor complex and inhibiting it during prior stimulation (in animals).
In vitro, it acts by blocking the sodium channels (IC50 = 8.4 μM) and inhibits the release of a nociception mediator (glutamate).
In rats, it inhibits the animal's reaction to rectal and colic distension in different experimental models.
Adverse Effects
The following list of adverse reactions is derived from experience with clinical trials and post-market data.
According to the organ classification system, adverse reactions are listed below in order of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10000 to < 1/1000); very rare (< 1/10000); not known (cannot be estimated from available data).
Immune system disorders.
- Not known: hypersensitivity reactions (pruritus, urticaria, Quincke oedema and unusually anaphylactic shock) Skin and subcutaneous tissue disorders.
- Uncommon: rash.
- Not known: internet frequency: generalised maculopapular rash, erythema, eczema reactions and unusually severe skin reactions including cases of generalised acute exanthematic pustosis (AEP), erythema and subcutaneous tissue disorders.
- Not known: any adverse drug (probious) and adverse drug (probious) adverse drug reaction (probetic).
- Not known: suspected adverse drug reaction reporting.